Picture Kentro Design Is Key to Your Success Berlin 650x100px

Document › Details

Immatics N.V.. (3/23/22). "Press Release: Immatics Announces Full Year 2021 Financial Results and Corporate Update". Tübingen & Houston, TX.

	Organisation	Immatics N.V. (Nasdaq: IMTX)
	Group	Immatics (Group)
	Organisation 2	Bristol Myers Squibb Co. (BMS) (NYSE: BMY)
	Group	Bristol Myers Squibb (BMS) (Group)
	Product	IMA203 TCR-T candidate targeting PRAME (ACTengine)
	Product 2	ACTengine® cell therapy product
	Index term 2	BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme
	Person	Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
	Person 2	Valente, Nancy (Immatics 202203– Non-executive Board Director formerly at Genentech/Roche)

Original document
accessed by [iito] on 2022-09-05

Record changed: 2022-09-05

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Immatics (Group)

[1] Immatics N.V.. (10/10/22). "Press Release: Immatics Announces $110 Million Underwritten Offering of Ordinary Shares". Houston, TX & Tübingen....
[2] Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen....
[3] Immatics N.V.. (9/10/22). "Press Release: Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022". Houston, TX & Tübingen....
[4] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
[5] Immatics N.V.. (8/23/22). "Press Release: Immatics Announces First Cancer Patient Treated with Second-generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME". Houston, TX & Tübingen....
[6] Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX....
[7] Immatics N.V.. (6/7/22). "Press Release: Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer". Tübingen, Houston, T...
[8] Immatics N.V.. (6/2/22). "Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs". Tübingen, Houston, TX & New York, NY....
[9] Immatics N.V.. (12/14/21). "Press Release: Immatics and Bristol Myers Squibb Enter into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401". Tübingen, Houston, TX & New York, NY....
[10] Immatics N.V.. (9/29/20). "Press Release: Immatics Appoints Arnd Christ as Chief Financial Officer". Tübingen & Houston, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]